Image: Public domain | via Wikimedia Commons
Ren Jinsheng, the founder and Chairman of Simcere Pharmaceutical Group, is a prominent figure in the healthcare industry, with a net worth of $2.4 billion as of December 3, 2025. His wealth stems from his involvement in the pharmaceutical sector. Ren, at age 62, holds a Master of Business Administration from Nanjing Normal University and a diploma from Nanjing University of Chinese Medicine. He is responsible for the overall strategy and business operations of Simcere.
Ren Jinsheng was born in China and holds a diploma from Nanjing University of Chinese Medicine, along with a Master of Business Administration from Nanjing Normal University.
Ren Jinsheng founded Simcere Pharmaceutical Group in 1995. The company has grown to become a key player in the pharmaceutical industry, focusing on research and development. Simcere was the first bio and chemical pharmaceutical company in China to be listed on the NYSE in 2007, before completing privatization in 2013.
Simcere's strategy is driven by in-house R&D and collaboration, with strategic partnerships with biotech firms and research institutes. The company has research development centers in Nanjing, Shanghai, and Boston.
Specific philanthropy amounts could not be found via search.
Established Jiangsu Simcere, engaging in the sales, marketing, and distribution of pharmaceuticals.
Simcere became the first bio and chemical pharmaceutical company in China to be listed on the NYSE.
Completed the privatization of Simcere.
REAL description
"Importantly, the clinical results achieved in both the global and local trials have enabled QUVIVIQ to be approved with no psychotropic drug control labeling in China."
The name “Simcere” comes from the word “sincere”, which embodies our main principle of treating people with sincerity.
